Xarelto safe for Cardioverting Afib

September 3, 2014 1:25 PM

14 0

Cardiologists, who have switched atrial fibrillation patients, awaiting elective cardioversion to a novel oral anticoagulant (NOAC) such as rivaroxaban (Xarelto) might find soundness in a formula of X-VeRT, which found that 20 mg of rivaroxaban was as safe as warfarin in that setting.

Patients randomized to rivaroxaban were half as likely to have a heart attack or stroke during cardioversion, when compared with warfarin patients, 0.51 percent versus 1.02 percent (relative risk 0.50, 95 percent CI 0.15-1.73).

Read more

To category page